Developer docs
API playgroundTry for free, no card

Search company profiles

Kantum Pharma

Full company profile

uuid00032ve

Namestring
Kantum Pharma
Legal namestring
Kantum Pharma, Inc.
Company typeenum
Private
Founded yearint
2016
Short descriptiontext

Kantum Pharma is a privately held, preclinical-stage biotechnology company developing a therapeutic candidate for Acute Kidney Injury (AKI), targeting critical care clinicians. Founded in 2016 and based in Concord, New Hampshire, the company has raised approximately $3.53M to date.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersConcord, United States
HQ citystring
Concord
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Acute Kidney Injury therapy, AKI drug development, Critical care therapeutics, Nephrology pharmaceuticals, Biopharmaceutical drug development
Industry2 codes
PRIMARYHLAKAHAI
Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults)
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Acute Kidney Injury Therapeutics
No data
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kantum Pharma is a biotechnology company developing a specific therapy for Acute Kidney Injury (AKI) intended to help critical care clinicians prevent hundreds of thousands of deaths caused by AKI. The company operates in the AKI clinical trial pipeline and is pre-commercial, with its offering centered on a single AKI therapeutic candidate.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1AKI Therapeutic (development-stage)
CategoryAcute Kidney Injury Therapeutics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Peers8 records
TypeDirect peer
Description

Dutch clinical-stage biotech developing recombinant alkaline phosphatase (ilofotenase) for AKI, the most directly comparable AKI-focused therapy developer and a clear head-to-head competitor for Kantum's indication.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for critically ill patients including AKI and sepsis-associated kidney injury, with overlapping critical care nephrology focus.

TypeBroad incumbent
Description

Large rare disease biopharma with established nephrology franchise (e.g., aHUS, atypical hemolytic uremic syndrome), representing a potential strategic acquirer and broad incumbent in renal therapeutics.

TypeEmerging player
Description

Developer of the NEPHROCHECK Test, the leading FDA-cleared AKI biomarker diagnostic, adjacent to Kantum's therapeutic focus with overlapping critical care nephrology customer base.

5Thrasos Therapeutics
TypeDirect peer
Description

AKI therapeutics developer (acquired by Torrent Pharmaceuticals) that previously advanced a clinical-stage AKI candidate, illustrating both the competitive set and exit pathway for AKI-focused biotechs.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company with programs in AKI and renal protection, pursuing similar indication spaces through a comparable early-stage development model.

7Angion Biomedica
TypeDirect peer
Description

Clinical-stage biotech focused on renal disease and AKI, developing small molecule and biologic therapies targeting kidney injury pathways overlapping with Kantum's therapeutic focus.

TypeDirect peer
Description

Swedish biotech developing RMC-035 for AKI and cardiac surgery-associated kidney injury, directly competing in the same therapeutic area with a similar clinical-stage profile.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kantum Pharma

Acute Kidney Injury Therapeuticskantumpharma.com

Kantum Pharma is a privately held, preclinical-stage biotechnology company developing a therapeutic candidate for Acute Kidney Injury (AKI), targeting critical care clinicians. Founded in 2016 and based in Concord, New Hampshire, the company has raised approximately $3.53M to date.

Kantum Pharma firmographics

Firmographics
Name
Kantum Pharma
Legal name
Kantum Pharma, Inc.
Website
https://kantumpharma.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Kantum Pharma is a privately held, preclinical-stage biotechnology company developing a therapeutic candidate for Acute Kidney Injury (AKI), targeting critical care clinicians. Founded in 2016 and based in Concord, New Hampshire, the company has raised approximately $3.53M to date.
Ownership category
akta.pro rank

Kantum Pharma industry classification

Industry
Product category
Acute Kidney Injury Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAHAI
Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults)
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Acute Kidney Injury therapy
  • AKI drug development
  • Critical care therapeutics
  • Nephrology pharmaceuticals
  • Biopharmaceutical drug development

Where Kantum Pharma is headquartered

Location

Headquarters

HQ city
Concord
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kantum Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Kantum Pharma product offering

Product offering

Core offering

Kantum Pharma is a biotechnology company developing a specific therapy for Acute Kidney Injury (AKI) intended to help critical care clinicians prevent hundreds of thousands of deaths caused by AKI. The company operates in the AKI clinical trial pipeline and is pre-commercial, with its offering centered on a single AKI therapeutic candidate.

Differentiator

Problem solved

Functional benefit

Products and services

  • AKI Therapeutic (development-stage)

Companies that use Kantum Pharma

Customer profile

Ideal customer profiles1 record

Kantum Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Kantum Pharma partnerships and signals

Strategic signal

Scale indicators1 record

Kantum Pharma competitors and assessment

Company assessment

Direct peers

  • AM-Pharma: Dutch clinical-stage biotech developing recombinant alkaline phosphatase (ilofotenase) for AKI, the most directly comparable AKI-focused therapy developer and a clear head-to-head competitor for Kantum's indication.
  • Atox Bio: Clinical-stage biotech developing therapeutics for critically ill patients including AKI and sepsis-associated kidney injury, with overlapping critical care nephrology focus.
  • Thrasos Therapeutics: AKI therapeutics developer (acquired by Torrent Pharmaceuticals) that previously advanced a clinical-stage AKI candidate, illustrating both the competitive set and exit pathway for AKI-focused biotechs.
  • Quark Pharmaceuticals: Clinical-stage RNA therapeutics company with programs in AKI and renal protection, pursuing similar indication spaces through a comparable early-stage development model.
  • Angion Biomedica: Clinical-stage biotech focused on renal disease and AKI, developing small molecule and biologic therapies targeting kidney injury pathways overlapping with Kantum's therapeutic focus.
  • Guard Therapeutics (Guardia): Swedish biotech developing RMC-035 for AKI and cardiac surgery-associated kidney injury, directly competing in the same therapeutic area with a similar clinical-stage profile.

Broad incumbents

  • Alexion Pharmaceuticals (AstraZeneca Rare Disease): Large rare disease biopharma with established nephrology franchise (e.g., aHUS, atypical hemolytic uremic syndrome), representing a potential strategic acquirer and broad incumbent in renal therapeutics.

Emerging players

  • Astute Medical (bioMérieux): Developer of the NEPHROCHECK Test, the leading FDA-cleared AKI biomarker diagnostic, adjacent to Kantum's therapeutic focus with overlapping critical care nephrology customer base.

Market position

Customer concentration

Kantum Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kantum Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Kantum Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kantum Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kantum Pharma

What does Kantum Pharma do?

Kantum Pharma is a biotechnology company developing a specific therapy for Acute Kidney Injury (AKI) intended to help critical care clinicians prevent hundreds of thousands of deaths caused by AKI. The company operates in the AKI clinical trial pipeline and is pre-commercial, with its offering centered on a single AKI therapeutic candidate.

Is Kantum Pharma a public or private company?

Kantum Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kantum Pharma founded?

Kantum Pharma was founded in 2016. It employs 1 to 10 people.

Where is Kantum Pharma based?

Kantum Pharma is headquartered in Concord, United States, in the North America region.

Who are Kantum Pharma's main competitors?

Direct peers on record are AM-Pharma, Atox Bio, Thrasos Therapeutics, Quark Pharmaceuticals, Angion Biomedica and Guard Therapeutics (Guardia). Alexion Pharmaceuticals (AstraZeneca Rare Disease) is listed as a broad incumbent. Astute Medical (bioMérieux) is listed as an emerging player.

Does Kantum Pharma have an API?

No public API is recorded for Kantum Pharma.

What industry is Kantum Pharma in?

Kantum Pharma's product category is Acute Kidney Injury Therapeutics. Its primary akta.pro industry code is HLAKAHAI, Acute Kidney Injury (AKI) & Hospital Nephrology (Inpatient Consults), with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals